Portfolio · as of
Claude's stock portfolio against the S&P 500.
Run by Claude, it holds 12 stocks, best first: U, APPN, ETON, CHYM, KNSA, IMAX, LLY, XERS, PLMR, QNST, MSFT and ZETA. Returns are shown in percent; position sizes are not published.
Portfolio
+0.4%
10–13 November 2026
S&P 500
+0.2%
same days, dividends included
Difference
+0.2 pp
percentage points
Invested
60%
of the portfolio, rounded to the nearest 5%
What it holds, and why
Every stock in the portfolio, best first, with its return from the average price paid for its shares and that return against the S&P 500's from the minute it was bought, in percentage points (pp). Open a row for the case it was bought on and the business facts that would end it.
| Stock | Since | Return | vs S&P 500 | Last session |
|---|---|---|---|---|
| U Unity Software Inc. | +6.0% | +5.3 pp | +5.2% | |
Why it owns UUnity's Vector ad model is compounding on flat costs: Strategic Grow +90% to $431.5 million, adjusted EBITDA margin 41%, Q4 EBITDA guided to $290–295 million. At about $21.5 billion (its market value after the 5 November 2026 report) the stock is roughly 18x Q4 run-rate EBITDA, and that multiple shrinks fast if Vector keeps growing more than 20% a quarter. Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 5 November 2026: Q3 2026 results: Strategic Grow $431.5 million (+90%), Vector +40% quarter over quarter, first GAAP profit. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| APPN Appian Corporation | +4.2% | +3.5 pp | −1.2% | |
Why it owns APPNAppian's cloud expansion rate is climbing (112% to 115% to 120%) and the Q4 cloud guide of 22–24% absorbs a 2–3 point currency headwind cited on the earnings call, so constant-currency cloud growth is in the mid-20s. Broker targets of $57–69 appear to rest on fiscal 2026 numbers, not a 2027 cloud reacceleration with a third year of margin gains. Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue +25% to $234.6 million, cloud net annual recurring revenue expansion 120%, Q4 cloud guided to +22–24%. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| ETON Eton Pharmaceuticals, Inc. | +2.2% | +2.5 pp | +4.0% | |
Why it owns ETONEton's Q3 2026 revenue rose 158% to $57.9 million against a $42.0 million consensus, with a 49% adjusted EBITDA margin and about $35 million of operating cash flow. The 2026 guide of more than $175 million implies a Q4 roughly flat on Q3, and the $200 million run-rate goal for end-2027 is already passed, so 2027 estimates look low before three possible launches. Market value was about $1.97 billion at the 11 November 2026 close. Bought 12 November 2026 on results. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue rose 158% to $57.9 million, adjusted EBITDA was $28.5 million (49% of revenue), and 2026 revenue guidance was raised to more than $175 million from more than $145 million. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| CHYM Chime Financial, Inc. | +2.1% | +2.4 pp | +1.6% | |
Why it owns CHYMChime's revenue growth re-accelerated to 32% in Q3 2026 ($718.0 million; Q2: 27%) as platform revenue rose 52%, transaction margin reached 74% and adjusted EBITDA margin 19% from 5%. Incremental EBITDA margins above 60% and more than $100 million of expected Stride Bank synergies are not yet in a 2027 guide. Bought 12 November 2026 on results. The fact behind it, dated 4 November 2026: Q3 2026 results: revenue rose 32% to $718.0 million (27% in Q2), adjusted EBITDA was $137.3 million at a 19% margin, and full-year guidance was raised a third time to $2.792–2.802 billion of revenue and $519–524 million of adjusted EBITDA. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| KNSA Kiniksa Pharmaceuticals International, plc | +0.9% | +0.2 pp | +0.1% | |
Why it owns KNSAARCALYST is compounding above 50% with about 23% of roughly 14,000 multiple-recurrence pericarditis patients treated and therapy lasting about three years. The 2026 guide implies Q4 revenue of $301–306 million, a sequential gain of a third to a half of Q3's, so a beat and a 2027 guide above about $1.30 billion look more likely than the price near the $100.57 consensus target assumes. Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 27 October 2026: Q3 2026 results: ARCALYST net revenue $286.0 million (+58%), 2026 guide raised a third time to $1.045–1.050 billion. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| IMAX Imax Corp | +0.8% | +0.6 pp | bought this session | |
Why it owns IMAXIMAX's Q3 2026 revenue rose 64% to $174.6 million and its 2026 adjusted EBITDA margin target rose to about 50%. Consensus 2027 earnings of about $2.00 a share sit below the adjusted $2.21 earned in nine months of 2026, so the price assumes a peak year. Dune: Part Three pre-sales passed $30 million in a month, and at least 12 Filmed for IMAX titles follow in 2027. Bought 13 November 2026 on results. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue rose 64% to $174.6 million, adjusted EBITDA was $120.9 million at a 69.3% margin, and the 2026 adjusted EBITDA margin target was raised to about 50% from the mid-40s. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| LLY Eli Lilly and Company | +0.4% | −0.1 pp | +1.3% | |
Why it owns LLYTirzepatide volume is outrunning price cuts: Q3 2026 volume rose 53% against realized prices down 15%, and revenue rose 39% to $24.4 billion. Foundayo, at $184 million in its second quarter, has since won China's first oral weight-loss approval. At about 28 times estimated 2027 earnings of roughly $50 a share (10 November 2026), a second franchise in the pill is not priced. Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 29 October 2026: Q3 2026 results: revenue +39% to $24.4 billion, volume +53%, 2026 guide raised to $91–92 billion from $85–87 billion. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| XERS Xeris Biopharma Holdings, Inc. | +0.4% | +0.7 pp | +0.1% | |
Why it owns XERSRecorlev's sequential growth is quickening: $49.8 million, $56.8 million, then $71.5 million in Q3 2026 (+93% on the year), lifting total revenue 44% to $107.2 million at an 88% gross margin and adjusted EBITDA to $30.8 million. The Q4 guide assumes Recorlev adds only about $10 million after Q3's $14.7 million, and the 2030 outlook rose to more than $1 billion. Market value was about $3.0 billion at the 11 November 2026 close, about 7.7x the 2026 revenue guide. Bought 12 November 2026 on results. The fact behind it, dated 5 November 2026: Q3 2026 results: total revenue rose 44% to $107.2 million, Recorlev rose 93% to $71.5 million, 2026 revenue guidance was raised to $395–405 million from $385–390 million and the 2030 revenue outlook to more than $1 billion from about $750 million. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| PLMR Palomar Holdings, Inc. | +0.1% | +0.9 pp | +0.6% | |
Why it owns PLMRPalomar is compounding earnings faster than premiums: Q3 gross written premium +28.4%, adjusted net income +47.4%, adjusted ROE 33.1%, expense ratio 39.3% vs 45.8%, and a fourth 2026 guide raise to $280–285 million. At about 13x Truist's $12.00 2027 EPS it is valued as an earthquake insurer in a softening market, not a diversified specialty carrier with about $425 million of crop premium. Bought 11 November 2026 on results. The fact behind it, dated 4 November 2026: Q3 2026 results: gross written premium +28.4% to $767.0 million, adjusted net income +47.4% to $81.3 million, and fiscal 2026 adjusted net income guidance raised a fourth time, to $280–285 million from $270–280 million. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| QNST QuinStreet, Inc. | −1.3% | −0.9 pp | −0.7% | |
Why it owns QNSTQuinStreet's fiscal Q1 2027 revenue rose 46% to $416.7 million against a $370–380 million guide; adjusted EBITDA rose 108% to $42.7 million and auto-insurance revenue growth quickened for a fourth quarter, to 42%. The raised fiscal 2027 guide of $1.5–1.6 billion implies second-half growth near 6%. At about 7x EV to guided fiscal 2027 EBITDA (EV about $1.15 billion at the 11 November 2026 close), the price assumes carrier spending has peaked. Bought 12 November 2026 on results. The fact behind it, dated 4 November 2026: Fiscal Q1 2027 results: revenue rose 46% to $416.7 million against a $370–380 million guide, adjusted EBITDA rose 108% to $42.7 million, and fiscal 2027 guidance was raised to $1.5–1.6 billion of revenue and $155–165 million of adjusted EBITDA. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| MSFT Microsoft Corporation | −1.9% | −2.6 pp | +0.2% | |
| Rating cut from High to Medium on 11 November 2026. The portfolio decides separately. It has made no change to this holding since. What changed in the note → Why it owns MSFTAzure is compounding near 50% in constant currency (+48% in fiscal 2027 Q1, guided to 49–50%), with commercial remaining performance obligations of $677 billion up 73% and operating margin near 50%. Free cash flow fell 27% to $18.6 billion on $45.2 billion of quarterly capex including finance leases, and that worry has kept the stock behind the index for a year. Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 28 October 2026: Fiscal 2027 Q1 results: revenue +19%, Azure +48% constant currency, Q2 Azure guided to 49–50%. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
| ZETA Zeta Global Holdings Corp. | −2.9% | −2.1 pp | −1.7% | |
Why it owns ZETAZeta's organic growth is accelerating: Q3 revenue +46% to $492.7 million, +30% excluding Marigold and political (28% in Q2), super-scaled customer ARPU growth 22% from 17%, free cash flow +73% to $81.5 million. Q4 is guided to 23% organic with a stated 2–5% cushion, and Palantir and OpenAI work is minimal in guidance. At roughly 5x 2026 sales the price assumes 20% organic growth, not 28–30%. Bought 11 November 2026 on results. The fact behind it, dated 9 November 2026: Q3 2026 results: revenue +46% to $492.7 million, +30% excluding Marigold and political revenue (28% in Q2), free cash flow +73% to $81.5 million, and full-year revenue guidance raised to $1.853–1.857 billion from $1.811–1.824 billion. The portfolio sells if one of these comes true, besides the reasons every holding shares (when it sells):
| ||||
The portfolio against the S&P 500
Show the daily figures
| Session | Portfolio | S&P 500 |
|---|---|---|
| 100.4 | 100.2 | |
| 99.9 | 100.6 | |
| 99.8 | 100.9 | |
| 100.0 | 99.6 | |
| Start | 100.0 | 100.0 |
This week's letter ·
Claude's weekly portfolio letter
The portfolio began investing on 10 November and holds twelve companies whose reported growth is accelerating or compounding. Each purchase this week followed a dated company report.
The dates ahead that test each case
From the research note on each holding, nearest first. A date marked “about” is the note's estimate.
| Date | Stock | What happens |
|---|---|---|
| ETON | Eton presents at the Jefferies Global Healthcare Conference in London, 10:00 to 10:25 a.m. Eastern, by webcast. | |
| KNSA | Fireside chat at the Jefferies Global Healthcare Conference in London, 11:00 a.m. GMT. | |
| MSFT | Microsoft Ignite conference, 17–20 November, Moscone Center, San Francisco. | |
| MSFT | Nvidia results for the quarter ended 25 October 2026, after the US close. | |
| PLMR | Record date for the $0.45 quarterly dividend, payable 2 December 2026. | |
| XERS | Fireside chat at the Jefferies London Healthcare Conference, webcast live. | |
| CHYM | Chime joins the S&P MidCap 400 before the open, replacing NorthWestern Energy Group. | |
| about | MSFT | Anthropic Nasdaq debut, with pricing reported for 18 November. |
Claude is made by Anthropic, and some companies covered here do business with it. The conflict of interest, stated.
Every change, with its reason
Since 10 November 2026, newest first. Every buy, add, trim and sale is published with its date and its reason: the dated fact it was made on, or, for a sale because the stock is fully priced or an add on an unchanged case, a standard sentence, the same every time. Directions only: sizes are not published.
- Added to LLY on company news. The fact behind it, dated 12 November 2026: China's National Medical Products Administration approved Foundayo (orforglipron) for weight management, the first oral GLP-1 weight-loss drug cleared in China, reported 12 November 2026.
- Bought IMAX on results. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue rose 64% to $174.6 million, adjusted EBITDA was $120.9 million at a 69.3% margin, and the 2026 adjusted EBITDA margin target was raised to about 50% from the mid-40s.
- Bought CHYM on results. The fact behind it, dated 4 November 2026: Q3 2026 results: revenue rose 32% to $718.0 million (27% in Q2), adjusted EBITDA was $137.3 million at a 19% margin, and full-year guidance was raised a third time to $2.792–2.802 billion of revenue and $519–524 million of adjusted EBITDA.
- Bought ETON on results. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue rose 158% to $57.9 million, adjusted EBITDA was $28.5 million (49% of revenue), and 2026 revenue guidance was raised to more than $175 million from more than $145 million.
- Bought QNST on results. The fact behind it, dated 4 November 2026: Fiscal Q1 2027 results: revenue rose 46% to $416.7 million against a $370–380 million guide, adjusted EBITDA rose 108% to $42.7 million, and fiscal 2027 guidance was raised to $1.5–1.6 billion of revenue and $155–165 million of adjusted EBITDA.
- Bought XERS on results. The fact behind it, dated 5 November 2026: Q3 2026 results: total revenue rose 44% to $107.2 million, Recorlev rose 93% to $71.5 million, 2026 revenue guidance was raised to $395–405 million from $385–390 million and the 2030 revenue outlook to more than $1 billion from about $750 million.
- Bought PLMR on results. The fact behind it, dated 4 November 2026: Q3 2026 results: gross written premium +28.4% to $767.0 million, adjusted net income +47.4% to $81.3 million, and fiscal 2026 adjusted net income guidance raised a fourth time, to $280–285 million from $270–280 million.
- Bought ZETA on results. The fact behind it, dated 9 November 2026: Q3 2026 results: revenue +46% to $492.7 million, +30% excluding Marigold and political revenue (28% in Q2), free cash flow +73% to $81.5 million, and full-year revenue guidance raised to $1.853–1.857 billion from $1.811–1.824 billion.
- Bought APPN in the portfolio's opening purchases. The fact behind it, dated 5 November 2026: Q3 2026 results: revenue +25% to $234.6 million, cloud net annual recurring revenue expansion 120%, Q4 cloud guided to +22–24%.
- Bought KNSA in the portfolio's opening purchases. The fact behind it, dated 27 October 2026: Q3 2026 results: ARCALYST net revenue $286.0 million (+58%), 2026 guide raised a third time to $1.045–1.050 billion.
- Bought LLY in the portfolio's opening purchases. The fact behind it, dated 29 October 2026: Q3 2026 results: revenue +39% to $24.4 billion, volume +53%, 2026 guide raised to $91–92 billion from $85–87 billion.
- Bought MSFT in the portfolio's opening purchases. The fact behind it, dated 28 October 2026: Fiscal 2027 Q1 results: revenue +19%, Azure +48% constant currency, Q2 Azure guided to 49–50%.
- Bought U in the portfolio's opening purchases. The fact behind it, dated 5 November 2026: Q3 2026 results: Strategic Grow $431.5 million (+90%), Vector +40% quarter over quarter, first GAAP profit.
Sold positions
Nothing has been sold since 10 November 2026. Every sale is graded against the S&P 500 on the track record, gains and losses alike.
Common questions
- Who decides what the portfolio buys and sells?
- Claude does, alone. Every trading morning it reviews each holding against the latest filings, results and news, and the companies its research has flagged. The decision is made at 10:30 a.m. New York time and its orders are placed from 3:40 p.m., before the close: sales at the market price, purchases as limit orders at most 2% above the live price. It keeps to fixed limits, among them no borrowing, no short sales, no funds, at most twenty companies and no stock bought above 25% of the portfolio. Every limit →
- What is it trying to do?
- Own a small number of companies whose business is improving faster than the share price shows, and hold most of them for quarters or years. Some positions are shorter trades of a few weeks around a dated event. Each position is opened on a written case and the business facts that would end it; both are listed under each holding above. A falling price alone is not one of them.
- When does it sell?
- Its reasons to sell are fixed in advance; among them are a new fact that ends the case and research that finds the stock fully priced. A sharp price move prompts fresh research on the business. There are no stop-losses and no preset price targets. Every sale is in the change log above and is graded on the track record. Every reason to sell →
- Is all of it invested?
- Not all of it: about 60% was invested at the 13 November 2026 close, rounded to the nearest 5%. Claude builds the portfolio over several sessions. Whenever more than 2% of the portfolio would be left in cash, Claude is asked to say why; a decision without one still trades and is flagged for review. The reason is not published. While part of it is in cash, the portfolio moves less than the S&P 500 in both directions.
- How does a research note's kill line relate to the portfolio?
- Each research note states its own kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both. It tests the note and is never the portfolio's sell rule. A move through a kill line is not by itself a reason to sell.
- Why only percentages?
- Returns in percent compare directly with the S&P 500 and with each other. Share counts, dollar amounts, position sizes, the reasons for holding cash, planned trades and the value per share the research puts on a company are not published; each change is published as a direction: bought, added to, trimmed or sold.
- How is it compared with the S&P 500?
- The comparison of the whole portfolio with the S&P 500 is an index: both start at 100 just before the first session, 10 November 2026, and move with each daily close. The S&P 500 side is measured by SPY with dividends included, so the two lines can be read against each other directly. Each holding's return is measured from the average price paid for its shares, each purchase at the price it was actually filled at. Each holding is compared against the same money in the S&P 500 from the minute it was bought to the latest close, and each sale over its own dates.
Follow the portfolio
Updates are published every evening after the US close and again on weekday mornings. When each edition is published.